logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
03/07/2025
Kangteng Electronics' night trading saw its increase expand to nearly 8%, with the company stating that it is responding to the impact of US export restrictions on software and technology access for customers.
Latest
2 m ago
Citibank: The tariff deadline may be "irrelevant" for G10 currencies, but Japan should be watched.
2 m ago
The Citibank forex strategist believes that the upcoming July 9th tariff negotiation deadline is likely to be a "non-event" for G10 currencies. Citibank's basic forecast for the EU is that both sides will reach a framework agreement before July 9, with a 10% tariff rate extension, and negotiations will continue. Due to the recent strength of the euro, they speculate that such news may slightly benefit the euro but may not be a significant driving factor as many positive news has already been reflected in the euro price. On the issue of Japan, Citibank believes that the likelihood of reaching an agreement is decreasing due to recent comments by Trump. They stated, "The risk of a tariff increase in Japan seems highest." The bank expects the USD/JPY to rise to 150 this summer, then drop below 140 later this year as the Bank of Japan is expected to normalize policy and the yen will regain strength.
4 m ago
Song Pharmaceutical: The first batch of subjects in the 13-week Phase IIa study of small-molecule oral GLP-1R agonist ASC30 in the United States has completed dosing.
4 m ago
Ge Li Pharmaceutical announced on the Hong Kong Stock Exchange that the first batch of obese or overweight participants have been dosed with ASC30, a small molecule oral GLP-1R agonist, in the 13-week Phase IIa study in the United States. In the Phase Ib study in the United States, ASC30 once daily oral tablets showed a mean weight reduction of up to 6.5% relative to baseline after 4 weeks of treatment following placebo calibration. The top-line data for the 13-week Phase IIa study of ASC30 oral tablets is expected to be obtained in the fourth quarter of 2025.
4 m ago
China Electronics Optics Valley (00798.HK) spent HK$661,800 on July 3 to repurchase 2.7 million shares.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.